Mitrică Dana, Drug V L, Prelipcean Cristina Cijevschi, Stan Mărioara
Universitatea de Medicină Si Farmacie Gr T Popa Iasi, Facultatea de Medicină, Institutul de Gastroenterologie si Hepatologie Iaşi.
Rev Med Chir Soc Med Nat Iasi. 2008 Apr-Jun;112(2):313-20.
Hemorrhagic complications are common in patients with liver diseases and contribute to the morbidity and mortality associated to this condition. The liver plays a central role in the hemostatic process as here all clotting factors and their inhibitors are synthetized. Liver damage is commonly associated with variable impairment of hemostasis due to multiple causes: decreased synthesis of clotting and inhibitor factors, decreased clearance of activated factors, hyperfibrinolysis, accelerated intravascular coagulation, quantitative and qualitative platelet defects. Their clinical implications remain to be elucidated, so further studies addressing this issue are needed.
出血性并发症在肝病患者中很常见，并且会导致与该病症相关的发病率和死亡率。肝脏在止血过程中起着核心作用，因为所有凝血因子及其抑制剂都是在肝脏中合成的。由于多种原因，肝损伤通常与止血功能的不同程度受损有关：凝血因子和抑制因子合成减少、活化因子清除减少、纤维蛋白溶解亢进、血管内凝血加速、血小板数量和质量缺陷。它们的临床意义仍有待阐明，因此需要进一步开展针对这一问题的研究。
